Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. - DeLeon TT; Almquist DR; Kipp BR; Langlais BT; Mangold A; Winters JL; Kosiorek HE; Joseph RW; Dronca RS; Block MS; McWilliams RR; Kottschade LA; et al. (PloS one, 2020)